酪氨酸激酶抑制剂逆转黏附诱导的骨髓瘤细胞的耐药性.docVIP

酪氨酸激酶抑制剂逆转黏附诱导的骨髓瘤细胞的耐药性 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：酪氨酸激酶抑制剂逆转黏附诱导的骨髓瘤细胞的耐药性 1 文2：三七总皂苷部分逆转黏附诱导的骨髓瘤细胞耐药性 8 1材料和方法 8 参考文摘引言： 11 原创性声明（模板） 13 文章致谢（模板） 13 正文 酪氨酸激酶抑制剂逆转黏附诱导的骨髓瘤细胞的耐药性 文1：酪氨酸激酶抑制剂逆转黏附诱导的骨髓瘤细胞的耐药性 Tyrosine Kinase Inhibitor Revees Adriamycin Resistance Mediated by Cell Adhesion in RPMI8226 Cells Abstract To study the effects of tyrosine-kinase inhibitor STI571 on the adhesion of RPMI8226 cells to fibronectin(FN)，cell adhesion mediated adriamycin-resistance and the Rac1 mRNA expression，the adhesion of RPMI8226 cells to fibronectin and drug resistance mediated by cell adhesion were determined by mea of crystal violet staining and MTT assays respectively，Rac1 mRNA levels in RPMI8226 cells were examined by semi-quantitative results showed that STI571 could inhibit the adhesion of RPMI8226 cells to RPMI8226 cells had been adhe-red to FN or BSA-coated wells for 1，6 and 12 hou，the adhesion rates were (±)%，(±)%，and (±)% treatment with STI571 20 μmol/L，the adhesion rates decreased to (±)%，(±)% and (±)% respectively (P＜).The experiment revealed that growth of RPMI8226 cells adhered to FN-coated plates had a significant advantage over growth on BSA-coated plates when exposed to adriamycin (Adr) for 1 hour followed by a 24-hour culture period，and the mean IC50 value for FN-adhered cells was (±) μmol/L while mean IC50 value for BSA control was (±)μmol/L (P＜).Following treatment with 20 μmol/L STI571，the mean IC50 values for FN and BSA adhered cells were (±)μmol/L，(±)μmol/L respectively，there was no significant difference between them（P＞）.RT-PCR demotrated that the relative Rac1 mRNA level (Rac1/GAPDH) in RPMI8226 cells was downregulated following being treated with 20μmol/L is concluded that STI571 can inhibit the adhesion of RPMI8226 cells to fibronectin，revee cell adhesion mediated adriamycin-resistance，and downregulate Rac1 mRNA level. Key words tyrosine-kinase inhibitor; STI571; myeloma cell; RPMI8226 cell; adhesion; drug resista